FDG PET/CT在CA-125升高患者中检测卵巢癌复发的诊断价值:系统综述与Meta分析
该系统综述与Meta分析纳入截至2024年7月的PubMed、Embase和Cochrane Library文献,评估[18F]FDG PET/CT在CA-125升高患者中检测卵巢癌复发的诊断效能。汇总敏感度为0.94(95%CI 0.89-0.97),特异度为0.89(95%CI 0.71-0.96),AUC为0.97(95%CI 0.95-0.98)。结论认为[18F]FDG PET/CT是检测此类患者卵巢癌复发的有效工具。
要点
- CA-125升高患者中,[18F]FDG PET/CT检测卵巢癌复发的汇总敏感度为0.94,特异度为0.89。
- 汇总AUC达0.97(95%CI 0.95-0.98),提示诊断准确度较高。
- 汇总阳性似然比7.11,阴性似然比0.07,诊断比值比99.20。
核心结论
- [18F]FDG PET/CT在CA-125升高的卵巢癌患者中检测复发具有高敏感度和特异度,可作为临床可靠的诊断方法;较既往仅限PET的Meta分析,整合PET/CT系统在提高特异度和减少假阳性方面显示附加价值。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Cochrane Library截至2024年7月的记录,纳入报告真阳性、假阳性、真阴性和假阴性数据的研究,排除重复、无全文、信息不完整无法提取数据、动物研究以及综述或系统综述,使用STATA 15.1分析。
诊断标准与关键数值
- 汇总敏感度0.94(95%CI 0.89-0.97),汇总特异度0.89(95%CI 0.71-0.96),阳性似然比7.11(95%CI 2.75-18.38),阴性似然比0.07(95%CI 0.03-0.15),诊断比值比99.20(95%CI 26.66-369.14),AUC 0.97(95%CI 0.95-0.98)。
临床应用与阅片要点
- 原文结论认为[18F]FDG PET/CT是检测CA-125升高患者卵巢癌复发的有效工具,结果支持其作为临床可靠诊断方法,并支持国际指南中的推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Elevated levels of cancer antigen-125 (CA-125) are strongly associated with the likelihood of ovarian cancer recurrence, making it a significant concern in clinical practice. [18F]FDG PET/CT has emerged as a valuable tool for detecting recurrent ovarian cancer. This study aims to evaluate the diagnostic performance of [18F]FDG PET/CT in identifying ovarian cancer relapse among patients exhibiting rising CA-125 levels, through a systematic review and meta-analysis.
METHODS: A comprehensive search was carried out across PubMed, Embase, and the Cochrane Library, encompassing all records up to July 2024. Studies were eligible for inclusion if they provided data on true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN) regarding the detection of ovarian cancer recurrence in patients with elevated CA-125 levels. Studies were excluded if they were duplicates, lacked full-text availability, contained incomplete information or were unable to be included in data extraction, involved animal studies, or were reviews or systematic reviews. The data were analysed using STATA version 15.1.
RESULTS: Across all included studies, the pooled sensitivity and specificity were 0.94 [95% confidence interval (CI): 0.89-0.97] and 0.89 (95% CI: 0.71-0.96), respectively. The positive likelihood ratio (LR+) was 7.11 (95% CI: 2.75-18.38), while the negative likelihood ratio (LR-) was 0.07 (95% CI: 0.03-0.15). The overall diagnostic odds ratio (DOR) amounted to 99.20 (95% CI: 26.66-369.14). Additionally, the area under the receiver operating characteristic curve (AUC) reached 0.97 (95% CI: 0.95-0.98).
CONCLUSION: With its high sensitivity and specificity, [18F]FDG PET/CT serves as an effective tool for detecting ovarian cancer recurrence in patients exhibiting elevated CA-125 levels. These results endorse its effectiveness as a dependable diagnostic method in clinical settings.
ADVANCES IN KNOWLEDGE: This meta-analysis provides updated pooled evidence that [18F]FDG PET/CT demonstrates excellent diagnostic accuracy (AUC 0.97) in detecting ovarian cancer recurrence in patients with elevated CA-125. Compared with earlier meta-analyses limited to PET alone, our findings highlight the added value of integrated PET/CT systems in improving specificity and reducing false positives, thereby supporting its recommendation in international guidelines and strengthening its role in clinical decision-making for recurrent ovarian cancer.
引用
- Zhou Q, Chen L, Zhu C, et al. The diagnostic value of FDG PET/CT in detecting ovarian cancer recurrence in patients with elevated CA-125 levels: a systematic review and meta-analysis. Br J Radiol. 2026. PMID: 41358952. doi:10.1093/bjr/tqaf291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。